{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:25:12Z","timestamp":1785392712430,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00467-020-04788-w","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T22:02:52Z","timestamp":1602712972000},"page":"1751-1764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["When should we start and stop ACEi\/ARB in paediatric chronic kidney disease?"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-6005","authenticated-orcid":false,"given":"Eugene Yu-hin","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison Lap-tak","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"Tullus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"4788_CR1","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1053\/j.ajkd.2015.01.008","volume":"65","author":"BA Warady","year":"2015","unstructured":"Warady BA, Abraham AG, Schwartz GJ, Wong CS, Mu\u00f1oz A, Betoko A, Mitsnefes M, Kaskel F, Greenbaum LA, Mak RH (2015) Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort. Am J Kidney Dis 65:878\u2013888","journal-title":"Am J Kidney Dis"},{"key":"4788_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2215\/CJN.07480714","volume":"10","author":"SA Fathallah-Shaykh","year":"2015","unstructured":"Fathallah-Shaykh SA, Flynn JT, Pierce CB, Abraham AG, Blydt-Hansen TD, Massengill SF, Moxey-Mims MM, Warady BA, Furth SL, Wong CS (2015) Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin J Am Soc Nephrol 10:571\u2013577","journal-title":"Clin J Am Soc Nephrol"},{"key":"4788_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1681\/ASN.2014090947","volume":"27","author":"R Shroff","year":"2016","unstructured":"Shroff R, Aitkenhead H, Costa N, Trivelli A, Litwin M, Picca S, Anarat A, Sallay P, Ozaltin F, Zurowska A (2016) Normal 25-hydroxyvitamin D levels are associated with less proteinuria and attenuate renal failure progression in children with CKD. J Am Soc Nephrol 27:314\u2013322","journal-title":"J Am Soc Nephrol"},{"key":"4788_CR4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"ESCAPE Trial Group","year":"2009","unstructured":"ESCAPE Trial Group (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639\u20131650","journal-title":"N Engl J Med"},{"key":"4788_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ki.1991.160","volume":"39","author":"A Remuzzi","year":"1991","unstructured":"Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G (1991) Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 39:1267\u20131273","journal-title":"Kidney Int"},{"key":"4788_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00467-008-0789-y","volume":"23","author":"E W\u00fchl","year":"2008","unstructured":"W\u00fchl E, Schaefer F (2008) Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol 23:705\u2013716","journal-title":"Pediatr Nephrol"},{"key":"4788_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin\u2013angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30\u201348","journal-title":"Ann Intern Med"},{"key":"4788_CR8","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group","year":"1997","unstructured":"The GISEN Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857\u20131863","journal-title":"Lancet"},{"key":"4788_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 135:73\u201387","journal-title":"Ann Intern Med"},{"key":"4788_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939\u2013945","journal-title":"N Engl J Med"},{"key":"4788_CR11","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1681\/ASN.2006101081","volume":"18","author":"DM Kent","year":"2007","unstructured":"Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, De Jong P, De Zeeuw D, Remuzzi G, Kamper A-L, Levey AS (2007) Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18:1959\u20131965","journal-title":"J Am Soc Nephrol"},{"key":"4788_CR12","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421\u20132431","journal-title":"JAMA"},{"key":"4788_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","volume":"365","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365:939\u2013946","journal-title":"Lancet"},{"key":"4788_CR14","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ (2013) Kidney disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int (Suppl 3):1-150"},{"key":"4788_CR15","doi-asserted-by":"publisher","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904","journal-title":"Pediatrics"},{"key":"4788_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1053\/j.ajkd.2018.06.010","volume":"72","author":"MR Weir","year":"2018","unstructured":"Weir MR, Lakkis JI, Jaar B, Rocco MV, Choi MJ, Kramer HJ, Ku E (2018) Use of renin-angiotensin system blockade in advanced ckd: An NKF-KDOQI controversies report. Am J Kidney Dis 72:873\u2013884","journal-title":"Am J Kidney Dis"},{"key":"4788_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2215\/CJN.09750819","volume":"15","author":"SM van den Belt","year":"2020","unstructured":"van den Belt SM, Heerspink HJ, Kirchner M, Gracchi V, Thurn-Valsassina D, Bayazit AK, Niemirska A, Canpolat N, Bulut IK, Azukaitis K (2020) Discontinuation of RAAS inhibition in children with advanced CKD. Clin J Am Soc Nephrol 15:625\u2013632","journal-title":"Clin J Am Soc Nephrol"},{"key":"4788_CR18","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","volume":"25","author":"AK Ahmed","year":"2010","unstructured":"Ahmed AK, Kamath NS, El Kossi M, El Nahas AM (2010) The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25:3977\u20133982","journal-title":"Nephrol Dial Transplant"},{"key":"4788_CR19","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1681\/ASN.V12122832","volume":"12","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti P, Perna A, Remuzzi G (2001) ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. J Am Soc Nephrol 12:2832\u20132837","journal-title":"J Am Soc Nephrol"},{"key":"4788_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354:131\u2013140","journal-title":"N Engl J Med"},{"key":"4788_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","volume":"174","author":"T-W Hsu","year":"2014","unstructured":"Hsu T-W, Liu J-S, Hung S-C, Kuo K-L, Chang Y-K, Chen Y-C, Hsu C-C, Tarng D-C (2014) Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 174:347\u2013354","journal-title":"JAMA Intern Med"},{"key":"4788_CR22","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456\u20131462","journal-title":"N Engl J Med"},{"key":"4788_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"4788_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"4788_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"S MacMahon","year":"2007","unstructured":"Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829\u2013840","journal-title":"Lancet"},{"key":"4788_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.7326\/0003-4819-156-8-201204170-00008","volume":"156","author":"HA Fink","year":"2012","unstructured":"Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ (2012) Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 156:570\u2013581","journal-title":"Ann Intern Med"},{"key":"4788_CR27","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"H-H Parving","year":"2001","unstructured":"Parving H-H, Lehnert H, Br\u00f6chner-Mortensen J, Gomis R, Andersen S, Arner P (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870\u2013878","journal-title":"N Engl J Med"},{"key":"4788_CR28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"JC Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL (1995) Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 123:754\u2013762","journal-title":"Ann Intern Med"},{"key":"4788_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","volume":"139","author":"TH Jafar","year":"2003","unstructured":"Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, De Jong PE, De Zeeuw D, Shahinfar S, Toto R, Levey AS (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139:244\u2013252","journal-title":"Ann Intern Med"},{"key":"4788_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","volume":"354","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359\u2013364","journal-title":"Lancet"},{"key":"4788_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/archinte.165.8.947","volume":"165","author":"J Lea","year":"2005","unstructured":"Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL (2005) The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 165:947\u2013953","journal-title":"Arch Intern Med"},{"key":"4788_CR32","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","volume":"352","author":"P Ruggenenti","year":"1998","unstructured":"Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252\u20131256","journal-title":"Lancet"},{"key":"4788_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1681\/ASN.V105997","volume":"10","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G (1999) In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 10:997\u20131006","journal-title":"J Am Soc Nephrol"},{"key":"4788_CR34","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG (2001) Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285:2719\u20132728","journal-title":"JAMA"},{"key":"4788_CR35","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.annepidem.2016.09.011","volume":"26","author":"DK Ng","year":"2016","unstructured":"Ng DK, Moxey-Mims M, Warady BA, Furth SL, Mu\u00f1oz A (2016) Racial differences in renal replacement therapy initiation among children with a nonglomerular cause of chronic kidney disease. Ann Epidimiol 26:780\u2013787.e781","journal-title":"Ann Epidimiol"},{"key":"4788_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547\u2013553","journal-title":"Lancet"},{"key":"4788_CR37","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","volume":"123","author":"SW Tobe","year":"2011","unstructured":"Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF (2011) Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 123:1098\u201311073","journal-title":"Circulation"},{"key":"4788_CR38","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892\u20131903","journal-title":"N Engl J Med"},{"key":"4788_CR39","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2215\/CJN.01780408","volume":"4","author":"CS Wong","year":"2009","unstructured":"Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, Kaskel F, Furth SL, Schwartz GJ (2009) Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol 4:812\u2013819","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl_9","key":"4788_CR40","first-page":"ix26","volume":"22","author":"W Metcalfe","year":"2007","unstructured":"Metcalfe W (2007) How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 22(suppl_9):ix26\u2013ix30","journal-title":"Nephrol Dial Transplant"},{"key":"4788_CR41","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1161\/HYPERTENSIONAHA.108.110635","volume":"52","author":"JT Flynn","year":"2008","unstructured":"Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, Warady BA (2008) Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 52:631\u2013637","journal-title":"Hypertension"},{"key":"4788_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2009060609","volume":"21","author":"M Mitsnefes","year":"2010","unstructured":"Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B, CKiD Study Group (2010) Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 21:137\u2013144","journal-title":"J Am Soc Nephrol"},{"key":"4788_CR43","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.117.09649","volume":"71","author":"G-M Barletta","year":"2018","unstructured":"Barletta G-M, Pierce C, Mitsnefes M, Samuels J, Warady BA, Furth S, Flynn J (2018) Is blood pressure improving in children with chronic kidney disease? A period analysis. Hypertension 71:444\u2013450","journal-title":"Hypertension"},{"key":"4788_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/HYPERTENSIONAHA.111.189266","volume":"60","author":"J Samuels","year":"2012","unstructured":"Samuels J, Ng D, Flynn JT, Mitsnefes M, Poffenbarger T, Warady BA, Furth S (2012) Ambulatory blood pressure patterns in children with chronic kidney disease. Hypertension 60:43\u201350","journal-title":"Hypertension"},{"key":"4788_CR45","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/ki.2013.352","volume":"85","author":"AJ Kogon","year":"2014","unstructured":"Kogon AJ, Pierce CB, Cox C, Brady TM, Mitsnefes MM, Warady BA, Furth SL, Flynn JT (2014) Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease. Kidney Int 85:938\u2013944","journal-title":"Kidney Int"},{"key":"4788_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00467-016-3512-4","volume":"32","author":"AG Abraham","year":"2017","unstructured":"Abraham AG, Betoko A, Fadrowski JJ, Pierce C, Furth SL, Warady BA, Mu\u00f1oz A (2017) Renin\u2013angiotensin II\u2013aldosterone system blockers and time to renal replacement therapy in children with CKD. Pediatr Nephrol 32:643\u2013649","journal-title":"Pediatr Nephrol"},{"key":"4788_CR47","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1681\/ASN.2018010036","volume":"29","author":"SM van den Belt","year":"2018","unstructured":"van den Belt SM, Heerspink HJ, Gracchi V, de Zeeuw D, W\u00fchl E, Schaefer F, ESCAPE Trial Group (2018) Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol 29:2225\u20132233","journal-title":"J Am Soc Nephrol"},{"key":"4788_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/archdischild-2016-310582","volume":"102","author":"E Snauwaert","year":"2017","unstructured":"Snauwaert E, Walle JV, De Bruyne P (2017) Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review. Arch Dis Child 102:63\u201371","journal-title":"Arch Dis Child"},{"key":"4788_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00246-016-1496-2","volume":"38","author":"LC Ku","year":"2017","unstructured":"Ku LC, Zimmerman K, Benjamin DK, Clark RH, Hornik CP, Smith PB (2017) Safety of Enalapril in infants admitted to the neonatal intensive care unit. Pediatr Cardiol 38:155\u2013161","journal-title":"Pediatr Cardiol"},{"key":"4788_CR50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0022-3476(88)83213-X","volume":"112","author":"ED Tack","year":"1988","unstructured":"Tack ED, Perlman JM (1988) Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 112:805\u2013810","journal-title":"J Pediatr"},{"key":"4788_CR51","doi-asserted-by":"publisher","first-page":"F110","DOI":"10.1152\/ajpcell.1995.269.1.C110","volume":"269","author":"A Tufro-McReddie","year":"1995","unstructured":"Tufro-McReddie A, Romano L, Harris J, Ferder L, Gomez R (1995) Angiotensin II regulates nephrogenesis and renal vascular development. Am J Phys 269:F110\u2013F115","journal-title":"Am J Phys"},{"key":"4788_CR52","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2016.11.003","volume":"91","author":"S Fr\u00f6lich","year":"2017","unstructured":"Fr\u00f6lich S, Slattery P, Thomas D, Goren I, Ferreiros N, Jensen BL, N\u00fcsing RM (2017) Angiotensin II-AT1\u2013receptor signaling is necessary for cyclooxygenase-2\u2013dependent postnatal nephron generation. Kidney Int 91:818\u2013829","journal-title":"Kidney Int"},{"key":"4788_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00467-018-3977-4","volume":"34","author":"MC Starr","year":"2019","unstructured":"Starr MC, Flynn JT (2019) Neonatal hypertension: cases, causes, and clinical approach. Pediatr Nephrol 34:787\u2013799","journal-title":"Pediatr Nephrol"},{"key":"4788_CR54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/kisup.2012.46","volume":"2","author":"GJ Becker","year":"2012","unstructured":"Becker GJ, Wheeler DC, De Zeeuw D, Fujita T, Furth SL, Holdaas H, Mendis S, Oparil S, Perkovic V, Rodrigues CIS (2012) Kidney disease: improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2:337\u2013414","journal-title":"Kidney Int Suppl"},{"key":"4788_CR55","first-page":"361","volume":"42","author":"AJ Jovanovich","year":"2015","unstructured":"Jovanovich AJ, Chonchol MB, Sobhi A, Kendrick JB, Cheung AK, Kaufman JS, Smits G, Jablonski KL, HOST Investigators (2015) Mineral metabolites, angiotensin II inhibition and outcomes in advanced chronic kidney disease. Am J Kidney Dis 42:361\u2013368","journal-title":"Am J Kidney Dis"},{"key":"4788_CR56","doi-asserted-by":"publisher","first-page":"e0170874","DOI":"10.1371\/journal.pone.0170874","volume":"12","author":"YJ Oh","year":"2017","unstructured":"Oh YJ, Kim SM, Shin BC, Kim HL, Chung JH, Kim AJ, Ro H, Chang JH, Lee HH, Chung W (2017) The impact of renin-angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease. PLoS One 12:e0170874","journal-title":"PLoS One"},{"key":"4788_CR57","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/ijcp.12475","volume":"68","author":"S Pita-Fern\u00e1ndez","year":"2014","unstructured":"Pita-Fern\u00e1ndez S, Chouci\u00f1o-Fern\u00e1ndez T, Juega-Puig J, Seoane-Pillado T, L\u00f3pez-Calvi\u00f1o B, P\u00e9rtega-D\u00edaz S, Pedreira-Andrade JD, Gil-Guill\u00e9n V (2014) A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. Int J Clin Pract 68:1231\u20131238","journal-title":"Int J Clin Pract"},{"key":"4788_CR58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/qjmed\/hcn039","volume":"101","author":"M Onuigbo","year":"2008","unstructured":"Onuigbo M, Onuigbo N (2008) Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. QJM 101:519\u2013527","journal-title":"QJM"},{"key":"4788_CR59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/ndt\/gfw166.13","volume":"31","author":"S Bhandari","year":"2016","unstructured":"Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, Cleland JG, Khwaja A, El Nahas M (2016) Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant 31:255\u2013261","journal-title":"Nephrol Dial Transplant"},{"key":"4788_CR60","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.2215\/CJN.08791209","volume":"5","author":"U Querfeld","year":"2010","unstructured":"Querfeld U, Anarat A, Bayazit AK, Bakkaloglu AS, Bilginer Y, Caliskan S, Civilibal M, Doyon A, Duzova A, Kracht D (2010) The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol 5:1642\u20131648","journal-title":"Clin J Am Soc Nephrol"},{"key":"4788_CR61","doi-asserted-by":"crossref","unstructured":"Kidney Disease Outcomes Quality Initiative (2004) K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(5 Suppl 1):S1-290","DOI":"10.1053\/j.ajkd.2004.03.003"},{"key":"4788_CR62","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","volume":"91","author":"CM Clase","year":"2017","unstructured":"Clase CM, Barzilay J, Gao P, Smyth A, Schmieder RE, Tobe S, Teo KK, Yusuf S, Mann JF (2017) Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 91:683\u2013690","journal-title":"Kidney Int"},{"key":"4788_CR63","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor\u2013associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160:685\u2013693","journal-title":"Arch Intern Med"},{"key":"4788_CR64","doi-asserted-by":"publisher","first-page":"j791","DOI":"10.1136\/bmj.j791","volume":"356","author":"M Schmidt","year":"2017","unstructured":"Schmidt M, Mansfield KE, Bhaskaran K, Nitsch D, S\u00f8rensen HT, Smeeth L, Tomlinson LA (2017) Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ 356:j791","journal-title":"BMJ"},{"key":"4788_CR65","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, De Zeeuw D, Thomas MC, Cooper ME, De Graeff PA, Hillege HJ, Parving H-H, Brenner BM, Shahinfar S, Heerspink HJL (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282\u2013287","journal-title":"Kidney Int"},{"key":"4788_CR66","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/archdischild-2011-300172","volume":"96","author":"K Tullus","year":"2011","unstructured":"Tullus K (2011) Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child 96:881\u2013882","journal-title":"Arch Dis Child"},{"key":"4788_CR67","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.2006121372","volume":"18","author":"FF Hou","year":"2007","unstructured":"Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP (2007) Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 18:1889\u20131898","journal-title":"J Am Soc Nephrol"},{"key":"4788_CR68","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.7006.1","volume":"4","author":"AQT Pham","year":"2015","unstructured":"Pham AQT, Xu LHR, Moe OW (2015) Drug-induced metabolic acidosis. F1000Res 4:F1000","journal-title":"F1000Res"},{"key":"4788_CR69","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/ndt\/gfp547","volume":"25","author":"M Frimodt-M\u00f8ller","year":"2010","unstructured":"Frimodt-M\u00f8ller M, H\u00f8j Nielsen A, Strandgaard S, Kamper A-L (2010) Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease. Nephrol Dial Transplant 25:842\u2013847","journal-title":"Nephrol Dial Transplant"},{"key":"4788_CR70","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"ONTARGET Investigators","year":"2008","unstructured":"ONTARGET Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547\u20131559","journal-title":"N Engl J Med"},{"key":"4788_CR71","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/ki.1995.238","volume":"47","author":"HP Hansen","year":"1995","unstructured":"Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving H-H (1995) Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 47:1726\u20131731","journal-title":"Kidney Int"},{"key":"4788_CR72","unstructured":"(FDA) FDA New Pediatric Labeling Information Database. https:\/\/www.accessdata.fda.gov\/scripts\/sda\/sdNavigation.cfm?sd=labelingdatabase"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-020-04788-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:23:49Z","timestamp":1650540229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-020-04788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4788"],"URL":"https:\/\/doi.org\/10.1007\/s00467-020-04788-w","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}